Konakion Pediátrico (Phytomenadione)

Phytomenadione serves as a cofactor for the gamma‑carboxylation of specific clotting factors (II, VII, IX, X). This modification enables the factors to bind calcium, which is essential for the assembly of the clotting cascade and the formation of a stable fibrin clot.

The dose of Konakion Pediátrico is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the route of administration. Only a qualified healthcare professional should set the appropriate regimen.

Safety data for phytomenadione in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Konakion Pediátrico is a pediatric‑focused formulation of phytomenadione, offering flexibility for intramuscular, intravenous, or oral administration. Compared with other vitamin K preparations, it is specifically licensed for use in newborns and children, and its dosing can be tailored to pediatric needs.

The product should be stored at 2‑8 °C, protected from light, and kept in its original packaging. It must not be frozen or shaken vigorously. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Konakion Pediátrico can be given by intramuscular injection, intravenous infusion, or oral administration, depending on the clinical indication and patient age. The route and technique should follow the prescribing clinician’s instructions and standard aseptic practices.

Serious risks include severe allergic reactions such as anaphylaxis, acute hemolysis, thrombosis or disseminated intravascular coagulation, and persistent bleeding despite treatment. Immediate medical attention is required if any of these events occur.

Patients with known hypersensitivity to phytomenadione or any excipients in the formulation should avoid its use. It is also contraindicated in individuals where abrupt reversal of anticoagulation is not medically indicated without proper supervision.